Chromadex Inc.

Elysium Health, Inc.

University of California

The Queen's University of Belfast

Universitat De Valéncia, Estudi General

Fundacion Universidad Catolica De Valencia San Vicente Martir

Ryan Dellinger

Mark Morris

Troy Rhonemus

Eric Marcotulli

Marie Eugenie Migaud

Philip Redpath

Richard Cunningham

Daniel Antonio Alminana

Dan Alminana

Leonard Pershing Guarente

Dietrich Conze

Amy Boileau

Kerri Crossey

Brian Nettles

Jeremy Bartos

Sylesh Venkataraman

Santiago Roel Santos

Aron Erickson

Frank L Meyskens

José María Estrela Arigüel

Hadi Casser

Rajesh Thamatam

José Enrique De La Rubia Orti

José Maria Estrela Ariguel

Rosario Salvador

Maria Elena Obrador Pla

José María Estrela ARIGÜEL

Infant formula compositions and methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development

Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside, pterostilbene and a phosphodiesterase (PDE) inhibitor, including a PDE4 inhibitor such as ibudilast, and also including a thiol/cysteine donor, such as acetylcysteine.

Methods and compositions for treating motor neuron diseases

Provided herein are methods and compositions related to treating and/or preventing liver related diseases and disorders and for improving liver health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.

Nicotinamide riboside for use in treating or preventing liver damage

Provided herein are crystalline forms of nicotinamide riboside chloride and methods of making the same. Also provided are compositions comprising the crystalline form of nicotinamide riboside chloride, and therapeutic methods employing the crystalline form of nicotinamide riboside chloride.

Crystalline forms of nicotinamide riboside chloride

Provided herein are methods and compositions related to treating motor neuron diseases, such as ALS, in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.

Treating and preventing motor neuron diseases using nicotinamide riboside

Provided herein are efficient and scalable methods for the synthesis of nicotinamide riboside from riboside triacetate. Also provided are compositions comprising nicotinamide riboside, and therapeutic methods employing nicotinamide riboside.

Methods of synthesizing nicotinamide riboside

Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.

Provided herein are methods and compositions related to treating and/or preventing kidney related diseases and disorders, treating and/or preventing acute kidney injury, and for improving kidney health in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside and/or pterostilbene.

Treating and preventing kidney damage

The present disclosure provides nicotinate/nicotinamide riboside compounds or derivatives of formula (I): wherein X, Z, Z, n, R, R, R, R, R, R, R, and Rare described herein, reduced analogs thereof, and synthetic processes for the preparation thereof.

B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof

Derivatives of nicotinic acid riboside (NAR), nicotinamide riboside (NR), and reduced NAR and NR, including 1-(2',3&#x2032;,5&#x2032;-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (4a), and compositions containing the same and/or reduced derivative forms of nicotinamide riboside including 1-(2&#x2032;,3&#x2032;,5&#x2032;-triacetyl-beta-D-ribofuranosyl)-1,4-nicotinamide (2), are provided for use in the care of treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing one or more NR, NAR, NRH, or NARH derivatives, or prodrugs or salts thereof. In further embodiments, the invention relates to methods of using one or more NR, NAR, NRH, or NARH derivatives, or prodrugs, solvates, or salts thereof, to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival and overall cell and tissue health.

Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions

Compositions are provided including nicotinic acid riboside ('NAR'), and derivatives thereof including 1-(2',3&#x2032;,5&#x2032;-triacetyl-beta-D-ribofuranosyl)-nicotinic acid ('NAR triacetate' or &#x201c;NARTA&#x201d;); or derivatives of a reduced form of nicotinic acid riboside (&#x201c;NARH&#x201d;), including 1-(2&#x2032;,3&#x2032;,5&#x2032;-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (&#x201c;NARH triacetate&#x201d; or &#x201c;NARH-TA&#x201d;); or derivatives of nicotinamide riboside (&#x201c;NR&#x201d;), including 1-(2&#x2032;,3&#x2032;,5&#x2032;-triacetyl-beta-D-ribofuranosyl)-nicotinamide (&#x201c;NR triacetate&#x201d; or &#x201c;NRTA&#x201d;); derivatives of a reduced form of nicotinamide riboside (&#x201c;NRH&#x201d;), including 1-(2&#x2032;,3&#x2032;,5&#x2032;-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (&#x201c;NRH triacetate&#x201d; or &#x201c;NRH-TA&#x201d;); or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. Methods of using the compounds above to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (&#x201c;NAD+&#x201d;) or NADH in cells and tissues for improving cell and tissue survival or overall cell and tissue health are provided.

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors

A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.

Growing community of inventors

Azusa, CA, United States of America

Ryan Dellinger